Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
暂无分享,去创建一个
Maria A. Rodriguez | Y. Oki | Ying Yuan | P. Mclaughlin | H. Macapinlac | A. Younes | L. Kwak | Lei Feng | N. Dang | L. Fayad | S. Neelapu | A. Goy | H. Chuang | B. Dabaja | M. Fanale | F. Hagemeister | B. Pro | J. Romaguera | F. Samaniego | A. Copeland | L. Feng | M. Rodriguez | Lei Feng
[1] J. Connors,et al. Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma , 2011 .
[2] Sean H. Lim,et al. Chemotherapy: Advanced Hodgkin lymphoma—balancing toxicity and cure , 2011, Nature Reviews Clinical Oncology.
[3] A. Rossi,et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. , 2011, The New England journal of medicine.
[4] T. Habermann,et al. Multicenter phase II study of rituximab-ABVD in classic Hodgkin lymphoma (cHL). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] A. Younes. Beyond chemotherapy: new agents for targeted treatment of lymphoma , 2011, Nature Reviews Clinical Oncology.
[6] R. Advani,et al. A Randomized Phase III Trial of ABVD Vs. Stanford V +/− Radiation Therapy In Locally Extensive and Advanced Stage Hodgkin's Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496) , 2010 .
[7] John P Leonard,et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.
[8] B. Coiffier,et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. , 2010, Blood.
[9] R. Greil,et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.
[10] Y. Oki,et al. Does Rituximab Have a Place in Treating Classic Hodgkin Lymphoma? , 2010, Current hematologic malignancy reports.
[11] V. Diehl,et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] V. Diehl,et al. Treatment of Hodgkin lymphoma: the past, present, and future , 2008, Nature Clinical Practice Oncology.
[13] L. Kaiser,et al. B-cell Depletion Using an Anti-CD20 Antibody Augments Antitumor Immune Responses and Immunotherapy in Nonhematopoetic Murine Tumor Models , 2008, Journal of immunotherapy.
[14] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Levis,et al. Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian- , 2007 .
[16] M. Siedner,et al. Clonotypic B Cells Circulate in Hodgkin’s Lymphoma (HL). , 2006 .
[17] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[18] J. Connors,et al. State-of-the-art therapeutics: Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Zelenetz,et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.
[20] A. Zelenetz,et al. Adverse prognostic significance of CD20 positive Reed–Sternberg cells in classical Hodgkin's disease * , 2004, British journal of haematology.
[21] V. Diehl,et al. Part II: Hodgkin's lymphoma--diagnosis and treatment. , 2004, The Lancet. Oncology.
[22] P. Mclaughlin,et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin disease , 2003, Cancer.
[23] Y. Natkunam,et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. , 2003, Blood.
[24] J. Connors,et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] V. Diehl,et al. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. , 2003, Blood.
[26] G. Bonadonna,et al. CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Olker,et al. A PROGNOSTIC SCORE FOR ADVANCED HODGKIN ’ S DISEASE , 2000 .
[28] J. Armitage,et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[30] K. Propert,et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.
[31] P. Isaacson,et al. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. , 1991, The American journal of pathology.
[32] N. Harris,et al. Coexpression of CD15 and CD20 by Reed-Sternberg cells in Hodgkin's disease. , 1991, The American journal of pathology.